Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Starting treatment news

Show

From To
Inflammation Persists Despite Very Early HIV Treatment

Biomarkers of inflammation increase during acute HIV infection and remain elevated despite early suppressive antiretroviral therapy, according to a study presented at CROI 2015, in Seattle, Washington.

Published
27 February 2015
From
The Body Pro
Starting HIV treatment at CD4 count above 500 reduces the risk of serious illness and death by 44%, African Temprano trial shows

Starting HIV treatment at a CD4 cell count above 500 reduced the risk of serious illness including tuberculosis (TB), and death, by 44% when compared to starting

Published
26 February 2015
By
Keith Alcorn
HIV Positive Guys Need To Consider Going On Meds Earlier — ACON

MORE HIV-positive men need to think about starting treatment straight after diagnosis if ambitious targets to end HIV transmission by 2020 are to be met, the head of New South Wales based LGBTI health body ACON has said. The comments come as the organisation launches a major new sexual health campaign that also aims to clear up confusion surrounding one of the newest buzzwords in the HIV lexicon: "undetectable".

Published
23 February 2015
From
Star Observer
The Search for a Permanent Alternative to HIV Drugs

Researchers Carefully Tailor a Study to Find Patients to Test Going Off Antiretroviral Medication

Published
16 February 2015
From
Wall Street Journal
HIV Organizations Urge Continuation of D:A:D Study

D:A:D follows 50,000 HIV-positive people, looking at drug safety and side effects over time. Results from D:A:D have changed HIV treatment guidelines, and how HIV-positive people are treated by their health care providers. We urge pharmaceutical companies to continue funding this vital study.

Published
11 February 2015
From
Treatment Action Group
No improvements in CD4 count at diagnosis in African patients in last decade

A study by Harvard Medical School has found that the average CD4 count in sub-Saharan African people who are diagnosed with HIV has not risen since 2002.

Published
04 February 2015
By
Gus Cairns
Starting HIV treatment early and then interrupting is no better than delaying it

A French study that looked at the total amount of time since infection that people with HIV have spent with a detectable viral load has found that,

Published
22 January 2015
By
Gus Cairns
Dolutegravir and Truimeq approved in England: London guidelines updated

On 14 January 2015, NHS England published the long awaited policy on dolutegravir and the fixed dose combination (FDC) of dolutegravir/abacavir/3TC (Triumeq). The London prescribing guidelines for first-line therapy have also been updated to include dolutegravir and Triumeq.

Published
14 January 2015
From
HIV i-Base
Study uncovers new ground about when to start HIV therapy

A major question that has recurred since the availability of potent combination anti-HIV therapy (commonly called ART or HAART) is when this therapy should be initiated to ensure the optimal health of HIV-positive people. New research has revealed that early therapy may be highly beneficial.

Published
13 January 2015
From
CATIE
Dolutegravir/abacavir/lamivudine: considerable added benefit for treatment-naive adults with HIV

Since September 2014, the fixed-dose combination of dolutegravir/abacavir/lamivudine (trade name Triumeq) has been approved for human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age. The Institute for Quality and Efficiency in Health Care (IQWiG), which had already assessed a dossier on dolutegravir in spring 2014, now examined in another dossier assessment whether the drug combination also offers an added benefit over the appropriate comparator therapy.

Published
12 January 2015
From
The Institute for Quality and Efficiency in Health Care
← First12345...66Next →

Filter by country